Loading...
XSTO
BONEX
Market cap1.46bUSD
Oct 09, Last price  
237.20SEK
1D
3.04%
1Q
-0.59%
IPO
688.04%
Name

Bonesupport Holding AB

Chart & performance

D1W1MN
XSTO:BONEX chart
P/E
109.27
P/S
13.22
EPS
2.17
Div yield, %
—
Shrs. gr., 5y
2.48%
Rev. gr., 5y
45.38%
Revenues
1.17b
+30.70%
40,961,00061,755,000104,599,000129,301,00096,623,000155,462,000180,860,000212,885,000328,818,000591,077,000898,727,0001,174,661,000
Net income
142m
+6.28%
-51,065,000-59,555,000-110,190,000-128,869,000-176,405,000-161,060,000-101,412,000-85,531,000-68,167,000245,021,000133,754,000142,154,000
CFO
221m
+236.53%
-45,923,000-65,292,000-81,933,000-107,534,000-171,625,000-163,828,000-100,275,000-83,421,000-46,985,000-18,257,00065,760,000221,304,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.

Key people

Torbjoern Skoeld
Chief Executive Officer · since 2025
Hakan Johansson
Chief Financial Officer · since 2022
Michael Diefenbeck
Executive Vice President - Medical and Clinical Affairs, Chief Medical Officer · since 2021
Michael Mortensen
Executive Vice President - Research and Development, Operations · since 2024
Michael Roth
General Manager, Executive Vice President - Commercial Operations North America · since 2024
Anna Stegmark
Executive Vice President - Quality Management & Regulatory Affairs · since 2024
Annelie Vikner
Executive Vice President - Global Marketing · since 2019
Fergus Macleod
General Manager, Executive Vice President - Commercial Operations EUROW · since 2019
Helena Brandt
Executive Vice President of Human Resources · since 2024
Director · since 2010
Director · since 2025
Lennart Johansson
Independent Chairman of the Board · since 2019
Mary O'Connor
Independent Director · since 2022
Independent Director · since 2022
IPO date
Jun 21, 2017
Employees
104
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Scheelevägen 19 A
Lund, M 223 70
SE
Address
Scheelevagen 19 A
Lund, M 223 70
SE
Previous name
Goldcup 5429 AB

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT